Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism].

L'Encephale - 1 Jan 2000

Reggiani K, Vandel P, Haffen E, Sechter D, Bizouard P, Vandel S

Abstract excerpt

The objective of this study was to assign metabolizer phenotype (cytochrome P450 2D6 or CYP2D6) to drug treated psychiatric adult patients to assess if the CYP2D6 polymorphism could be a potential risk factor for the development of extrapyramidal side effects of psychotropic drugs. Twenty-eight u...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents
Share to Antipsychotic Agents
Share to Basal Ganglia Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Gene Expression

Share to Mental Disorders

Share to Risk Factors

Source

Identifiers

PMID: 10875063

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-10875063-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism].PMID 10875063Read ↗

Drug extrapyramidal side-effects or not: is there a dextromethorphan phenotype difference?Semantic proximity Read ↗

Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes.Semantic proximity Read ↗

CYP 2D6 PM phenotype hypothesis of antidepressant extrapyramidal side-effects.Semantic proximity Read ↗

Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study.Semantic proximity Read ↗

Psychiatric Disorder or Adverse Drug Reaction? - How CYP2D6 Metabolizing Activity Can Result in Dextromethorphan Intoxication.Semantic proximity Read ↗

A CYP2D6 phenotype-genotype mismatch in Japanese psychiatric patients.Semantic proximity Read ↗

Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy.Semantic proximity Read ↗

CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication.Semantic proximity Read ↗

Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients.Semantic proximity Read ↗

CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients.Semantic proximity Read ↗

Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms.Semantic proximity Read ↗

[Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.